

Nurix Therapeutics, Inc. (NRIX)

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001549595

Nurix Therapeutics, Inc. NRIX; healthcare	
Grade	C A B C D E middle fifth of 371 graded peers percentile 50.0; sampling error 2.5 points; lower is stronger
Rank	186 of 371
Profitability	D percentile 75.6
Solvency	B percentile 30.4
Growth and financing	B/C percentile 38.6
Reliability	0.91 AUC filers with \$591M to \$2.67B assets; 95% interval 0.88 to 0.94; 160 events, 2020 to 2025
Peer failure rate	1.01% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	\$591M to \$2.67B assets total assets \$688.1M
Standard universe	inside revenue above \$1M and assets above \$10M
Warnings	dilution, short runway not computable: fortress balance sheet
Inputs computable	7 of 14
Graded from	filings received through Jan 28, 2026 254 days before the rescan; latest periodic filing 10-Q received Jul 9, 2026
Last close	\$22.20 2026-10-08; market equity \$2.3B
Price used in grade	None



C, the tortoise
middle fifth of its sector; letters are fifths of the 371 graded peers


Share price, twelve months to the rescan
split-adjusted close; the letter is fixed at the rescan that set it



Rescans on file: C from Aug 21, 2026

Letter at every rescan

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only



Business, in the company's words

opening of Item 1 of the 10-K received Jan 28, 2026

When used in this report, unless otherwise indicated, "Nurix," "Company," "we," "us" and "our" refers to Nurix Therapeutics, Inc. and its wholly owned subsidiaries. We are a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, the next frontier in innovative drug design aimed at improving treatment options for patients with cancer and inflammatory diseases.

The fourteen inputs

lower percentile is stronger; equal-weighted sleeves

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability, sleeve percentile 75.6						
Gross profitability		not computable	32.2%			one or more required annual facts are missing
Return on invested capital		not computable	9.3%			one or more required annual facts are missing
Accruals ratio		(2.2%)	(6.6%)	75.6	811	2025-11-30
Gross margin stability, five years		not computable	2.8 pts			five annual gross margins are required; found 0
Solvency, sleeve percentile 30.4						
Twelve-month failure probability		0.05%	0.07%	34.0	248	2026-05-31
Altman Z double-prime		1.20	(0.31)	31.7	756	2025-11-30
Net debt to EBITDA		not computable	1.82x			one or more required annual facts are missing
Interest coverage		not computable	(4.51x)			one or more required annual facts are missing
Current ratio		7.02x	2.96x	25.4	839	2025-11-30
Growth and financing, sleeve percentile 38.6						
Revenue growth, three-year compound		29.5%	10.0%	22.5	415	2025-11-30
Free cash flow growth, three-year compound		not computable	10.9%			current FCF must be positive and base FCF must exceed \$100,000
Reinvestment rate		not computable	37.1%			one or more required annual facts are missing
Asset growth, three years		18.2%	2.1%	22.8	704	2025-11-30
Net share issuance, one year		35.5%	2.5%	70.5	634	2026-01-23


Warnings

2 of 7 checks triggered; none of them enters the letter

Check	Measured
Dilution	split-adjusted year-over-year share growth is 35.5%
Short runway	cash runway is 2.8 months

Among 371 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
181	Macrogenics Inc. (MGNX)	48.6	C	
182	Savara Inc. (SVRA)	48.9	C	short runway, fortress balance sheet
183	Biosesix Inc. (BDSX)	49.2	C	dilution
184	Evolus, Inc. (EOLS)	49.5	C	
185	Neogen Corp. (NEOG)	49.7	C	late filer
186	Nurix Therapeutics, Inc. (NRIX) <	50.0	C	dilution, short runway
187	Pacira BioSciences, Inc. (PCRX)	50.3	C	
188	Neuroone Medical Technologies Corp. (NMTC)	50.5	C	short runway, fortress balance sheet
189	RadNet, Inc. (RDNT)	50.8	C	
190	Schrodinger, Inc. (SDGR)	51.1	C	
191	Zai Lab Ltd. (ZLAB)	51.4	C	

What the price implies

at the 2026-10-08 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	179.0%	8.0%	95
Distance from 52-week high	(20.1%)	(31.4%)	65
EBIT to enterprise value	not computable	(1.5%)	
Free cash flow yield	(11.4%)	(1.0%)	30
Book value to price	0.17	0.28	37
Sales to price	0.04	0.31	13
Composite equity issuance, five years	98.1%	20.3%	77
Relative strength against the sector, log excess return	0.81	(0.14)	95

Diagnostics

not in the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-11-30	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	pass
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	pass
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	\$67.7M

Operating cash flow, four quarters	-\$293.7M
Months of runway	2.8
Days since last periodic filing	92 (10-Q received Jul 9, 2026)
Median daily dollar volume, 63 sessions	\$31.0M

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	net income	us-gaap:NetIncomeLoss	-\$264.5M	2025-11-30	2026-01-28	10-K	0001549595-26-000016
2	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$249.5M	2025-11-30	2026-01-28	10-K	0001549595-26-000016
3	assets	us-gaap:Assets	\$688.1M	2025-11-30	2026-01-28	10-K	0001549595-26-000016
4	assets	us-gaap:Assets	\$669.3M	2024-11-30	2026-01-28	10-K	0001549595-26-000016
5	current assets	us-gaap:AssetsCurrent	\$606.8M	2025-11-30	2026-01-28	10-K	0001549595-26-000016
6	current liabilities	us-gaap:LiabilitiesCurrent	\$86.5M	2025-11-30	2026-01-28	10-K	0001549595-26-000016
7	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-\$1.0B	2025-11-30	2026-01-28	10-K	0001549595-26-000016
8	operating income	us-gaap:OperatingIncomeLoss	-\$285.7M	2025-11-30	2026-01-28	10-K	0001549595-26-000016
9	book equity	us-gaap:StockholdersEquity	\$538.7M	2025-11-30	2026-01-28	10-K	0001549595-26-000016
10	liabilities	us-gaap:Liabilities	\$149.4M	2025-11-30	2026-01-28	10-K	0001549595-26-000016
11	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$84.0M	2025-11-30	2026-01-28	10-K	0001549595-26-000016
12	revenue	us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax	\$54.5M	2024-11-30	2026-01-28	10-K	0001549595-26-000016
13	revenue	us-gaap:Revenues	\$77.0M	2023-11-30	2024-02-15	10-K	0001549595-24-000025
14	revenue	us-gaap:Revenues	\$38.6M	2022-11-30	2024-02-15	10-K	0001549595-24-000025
15	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$14.0M	2025-11-30	2026-01-28	10-K	0001549595-26-000016
16	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$172.6M	2024-11-30	2026-01-28	10-K	0001549595-26-000016
17	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$9.3M	2024-11-30	2026-01-28	10-K	0001549595-26-000016
18	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$81.4M	2023-11-30	2026-01-28	10-K	0001549595-26-000016
19	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$8.4M	2023-11-30	2026-01-28	10-K	0001549595-26-000016
20	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$159.8M	2022-11-30	2025-01-28	10-K	0001549595-25-000016
21	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$12.2M	2022-11-30	2025-01-28	10-K	0001549595-25-000016
22	assets	us-gaap:Assets	\$355.6M	2023-11-30	2025-01-28	10-K	0001549595-25-000016
23	assets	us-gaap:Assets	\$416.8M	2022-11-30	2024-02-15	10-K	0001549595-24-000025
24	shares outstanding	dei:EntityCommonStockSharesOutstanding	102,843,012	2026-01-23	2026-01-28	10-K	0001549595-26-000016
25	shares outstanding	dei:EntityCommonStockSharesOutstanding	75,886,817	2025-01-24	2025-01-28	10-K	0001549595-25-000016